Inhibition of tryptase release from human colon mast cells by histamine receptor antagonists.

The main objective of this study was to investigate the ability of histamine receptor antagonists to modulate tryptase release from human colon mast cells induced by histamine. Enzymatically dispersed cells from human colon were challenged with histamine in the absence or presence of the histamine receptor antagonists, and the tryptase release was determined. It was found that histamine induced tryptase release from colon mast cells was inhibited by up to approximately 61.5% and 24% by the H1 histamine receptor antagonist terfenadine and the H2 histamine receptor antagonist cimetidine, respectively, when histamine and its antagonists were added to cells at the same time. The H3 histamine receptor antagonist clobenpropit had no effect on histamine induced tryptase release from colon mast cells at all concentrations tested. Preincubation of terfenadine, cimetidine or clobenpropit with cells for 20 minutes before challenging with histamine did not enhance the ability of these antihistamines to inhibit histamine induced tryptase release. Apart from terfenadine at 100 microg/ml, the antagonists themselves did not stimulate tryptase release from colon mast cells following both 15 minutes and 35 minutes incubation periods. It was concluded that H1 and H2 histamine receptor antagonists were able to inhibit histamine induced tryptase release from colon mast cells. This not only added some new data to our hypothesis of self-amplification mechanisms of mast cell degranulation, but also suggested that combining these two types of antihistamine drugs could be useful for the treatment of inflammatory bowel disease (IBD).

[1]  Hua Xie,et al.  Modulation of tryptase secretion from human colon mast cells by histamine. , 2004, World journal of gastroenterology.

[2]  Shao-heng He.  Key role of mast cells and their major secretory products in inflammatory bowel disease. , 2004, World journal of gastroenterology.

[3]  E. Crivellato,et al.  Low mast cell density in the human duodenal mucosa from chronic inflammatory duodenal bowel disorders is associated with defective villous architecture , 2003, European journal of clinical investigation.

[4]  E. Hahn,et al.  Enhanced histamine metabolism: a comparative analysis of collagenous colitis and food allergy with respect to the role of diet and NSAID use , 2003, Inflammation Research.

[5]  H. Isomoto,et al.  Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. , 2002, Hepato-gastroenterology.

[6]  M. Buckley,et al.  Roles of the mast cell and basophil in asthma , 2001 .

[7]  C. O'Morain,et al.  Increased mast cells in the irritable bowel syndrome , 2000, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[8]  S. Galli.  Mast cells and basophils , 2000, Current opinion in hematology.

[9]  W. Falk,et al.  Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin , 1999, Gut.

[10]  W. Beil,et al.  Number, fixation properties, dye-binding and protease expression of duodenal mast cells: comparisons between healthy subjects and patients with gastritis or Crohn’s disease , 1997, The Histochemical Journal.

[11]  L. Schwartz,et al.  Mast cell activation in arthritis : detection of α- and β-tryptase, histamine and eosinophil cationic protein in synovial fluid , 1997 .

[12]  A. Walls,et al.  Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation. , 1997, European journal of pharmacology.

[13]  G. Sant,et al.  Mast cell and substance P-positive nerve involvement in a patient with both irritable bowel syndrome and interstitial cystitis. , 1996, Urology.

[14]  M. Manns,et al.  Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease , 1996, Histopathology.

[15]  E. Hahn,et al.  Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. , 1995, International Archives of Allergy and Immunology.

[16]  G. Coruzzi,et al.  An update on histamine H3 receptors and gastrointestinal functions , 1995, Digestive Diseases and Sciences.

[17]  L. Lichtenstein,et al.  Intestinal mast cell responses in idiopathic inflammatory bowel disease , 1993, Digestive Diseases and Sciences.

[18]  W. Schunack,et al.  The influence of H1-, H2- and H3-receptors on the spontaneous and ConA induced histamine release from human adenoidal mast cells , 1991, Agents and Actions.

[19]  O. Ahrenstedt,et al.  The jejunal secretion of histamine is increased in active Crohn's disease. , 1990, Gastroenterology.

[20]  M. Gulubova,et al.  Mast cells and inflammatory mediators in chronic ulcerative colitis. , 2002, Acta histochemica.

[21]  A. Walls.  Chapter 19 – Structure and Function of Human Mast Cell Tryptase , 2000 .

[22]  E. Hahn,et al.  Evidence for mast cell activation in collagenous colitis , 1998, Inflammation Research.

[23]  P. Rangachari.  Histamine: mercurial messenger in the gut. , 1992, The American journal of physiology.